Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. - Wikidata - thesis-toulmin - TriplyDB

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

http://www.wikidata.org/entity/Q37344577

about

Treatment of multiple myeloma bone disease: experimental and clinical data.The oxidation states of DJ-1 dictate the cell fate in response to oxidative stress triggered by 4-hpr: autophagy or apoptosis?Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells.Mitochondria: redox metabolism and dysfunction.Fenretinide prevents lipid-induced insulin resistance by blocking ceramide biosynthesis Fenretinide inhibited de novo ceramide synthesis and proinflammatory cytokines induced by Aggregatibacter actinomycetemcomitans.Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo.Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.

P2860

Q30868833-DD87AF8B-D888-4023-842E-187916367FF8 Q34154615-7FCEF000-B277-4E5F-87E0-16B53BF3D82A Q34652128-CC40956E-2321-4E6D-8DFD-155B96C2ED67 Q35944831-0FD0E0C0-FABE-4E6C-814B-F771D9BA6A69 Q36006997-9645D83D-9B7D-4FFC-AAD9-31313EFC6B6B Q36462058-DBE81B3B-129E-4119-94DD-29B4D1BC3B75 Q39241504-627FE33B-4001-4339-9DCC-1E4D81AD8515 Q39377326-B2BB8BAB-0EB1-4451-B7C6-6D58185AAF23

P2860

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

http://www.wikidata.org/entity/Q37344577

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

@en

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

@nl

type

label

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

@en

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

@nl

prefLabel

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

@en

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

@nl

P1433

Q37344577-0DDE52CD-6BD8-4C18-A798-024695686AF6

P1476

Q37344577-4B0D42BE-FC22-48B8-B38A-299E9848BB8E

P2093

Q37344577-23BE2D0F-5B98-4AF1-941F-D4C68C9F5652

Q37344577-71A64673-01E8-43D0-A3CA-A8C2219A463A

Q37344577-DF66A9A6-2F01-41A3-A023-9F3EC474806F

Q37344577-F27625E4-261A-4E04-ADDA-A7AC6316E7B9

P2860

Q37344577-002F1161-E232-400A-AB43-E1A2779A14B9

Q37344577-1CFF7B6D-AA08-4B1A-B672-F3EA2AF02DB9

Q37344577-23D695B7-D3E1-43F1-8065-9128CAE7185E

Q37344577-2925AA60-A288-4B02-864B-B75BB9E12515

Q37344577-2DB345F5-04BB-45C0-A03A-3DB1716A3337

Q37344577-3C1E7461-42E2-420D-9846-CD087BB5F82F

Q37344577-3DDD0A5B-E549-4377-848D-7E06570CE3B3

Q37344577-3E4036EC-DD5B-453C-9D23-50CFBE2A04E2

Q37344577-5193575E-C1E6-4F67-8D10-9668772BF349

Q37344577-528AAE09-8AAB-4234-BC91-FB7C0AF9A970

P304

Q37344577-44033315-7483-4804-B8D0-B2269C919A3D

P31

Q37344577-38034471-9BC9-4101-AF57-A4BAC2F24C69

P356

Q37344577-06A2D75C-0626-4703-96A9-7BADDC82BA25

P407

Q37344577-4C32FEF6-AC4E-4C23-AAAA-5F35EC4109FD

P433

Q37344577-B71F89F0-5F3E-4D84-A2BE-DB2BD5509AF3

P478

Q37344577-14FD8648-F165-4405-AACB-56810642A3AD

P50

Q37344577-972CED19-16FB-484A-801C-3E04C7827B5F

P577

Q37344577-CFFE576C-FF9D-45E3-B418-9021BF583581

P5875

Q37344577-D84DA7F5-6210-43AC-9E9A-5AB08F0721B0

P698

Q37344577-6FCE9254-ECDD-4C45-8471-0FDA11FAB77B

P932

Q37344577-3BEC5FF9-7E82-4EAB-83AF-D75D2B9ABF3C

P356

J.CANLET.2009.04.022

P1433

P1476

Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

@en

P2093

Angela Pennisi

http://www.w3.org/2001/XMLSchema#string

Sharmin Khan

http://www.w3.org/2001/XMLSchema#string

Wen Ling

http://www.w3.org/2001/XMLSchema#string

Xin Li

http://www.w3.org/2001/XMLSchema#string

P2860

Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling

Mechanism of fenretinide (4-HPR)-induced cell death

Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure

Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring.

Fenretinide and its relation to cancer.

Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer.

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

Bone marrow angiogenesis and progression in multiple myeloma.

Angiogenesis and cancer prevention: a vision.

N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells

P304

175-181

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CANLET.2009.04.022

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24431885

http://www.w3.org/2001/XMLSchema#string

P698

19446953

http://www.w3.org/2001/XMLSchema#string

P932

2743080

http://www.w3.org/2001/XMLSchema#string